Theravance Biopharma, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- Paradium AI (PAAI) Halted, News Pending
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Theravance Biopharma (TBPH) Tops Q3 EPS by 5c, Revenues Miss
November 6, 2018 4:57 PM ESTTheravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($1.10), $0.05 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $14.06 million.
Rick E Winningham, chairman and chief executive officer, commented: "The steps we have taken over the course of the year reflect a focus on our strategic... More
